USFDA issues 10 observations for Zydus Lifesciences Jarod facility
Ahmedabad: Zydus Lifesciences has informed in a BSE filing that the US Food and Drug Administration (USFDA) has concluded an inspection with 10 observations at the Company's Injectable Manufacturing site situated at Jarod, near Vadodara.
The inspection was conducted from April 15 to April 23, 2024.
"The Company will closely work with the USFDA to address and respond to the observations in an expeditious manner," Zydus stated in a BSE filing.
Read also: New Drug Application of Zydus Desidustat tablets by China Medical System Holdings accepted in China
Headquartered in Ahmedabad, Zydus Lifesciences Limited is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group has a significant presence in cancer-related therapies and offers a wide range of solutions with cytotoxic, supportive & targeted drugs. The group employs over 26,000 people worldwide, including 1,400 scientists engaged in R&D.
Read also: Zydus Gets CDSCO Panel Nod To Manufacture Market Letermovir 240 mg, 480 mg Tablet
